Build an Inve Case for MTLS → Read the full call →
Materialise (MTLS) earnings
Materialise earnings: last reported Thu, 27 Aug 2026, for the quarter ended Jun 2026.
Materialise earnings callsMaterialise earnings calls (MTLS)
Latest concall · Q2 2026 · call held call held 27 Aug 2026
Materialise Q2 FY26 — Strong Profitability Expansion and Strategic Portfolio Sharpening
What went well
- Consolidated revenue grew by over 8% year-on-year to EUR 70.1 million.
- Adjusted EBIT reached EUR 3.9 million, expanding margin to 5.5%, reflecting stronger operating leverage.
- Medical segment revenue grew by over 12% year-on-year, reinforcing its position as the primary growth engine.
What to watch
- Software segment revenue declined by 3% year-on-year due to cautious customer spending and extended sales cycles in the industrial environment.
- Medical Software segment revenue was down 4%, partly due to reduced research grants in the U.S. academic segment and cautiousness from customers due to reimbursement changes.
Performance +54.0% 1Y
1Y: $5.56 on 29 Sept 2025 → $8.56. High $8.75 (29 Sept 2026), low $4.8 (27 Mar 2026).
Balance sheet
| Year ending | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|
| Fixed assets | $102.24M | $108.31M | $95.65M | $100.55M | $105.42M | $115.66M |
| Total assets | $392.52M | $399.94M | $468.23M | $438.65M | $438.28M | $411.75M |
How to read this
As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of MTLS filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.